Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute, introduces New Jersey's new state-of-the-art facilities at the Jack & Sheryl ...

With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway.

Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of reditary ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Panelists discuss the specific challenges and barriers clinicians might encounter when utilizing different BTK inhibitors ...

Panelists discuss potential changes to clinical pathways for Bruton tyrosine kinase (BTK) inhibitor therapies as a result of ...

A panelist discusses the latest advancements presented at ASCO 2025, highlighting talquetamab’s pivotal trial in relapsed/refractory multiple myeloma that demonstrated high response rates and longer ...

Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP ...

Learning the best type of HIV prevention for those at highest risk can start with conversations about their options, writes ...

B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City, reflects on how the reality of COVID-19 infection proved far more complex than ...

As clinician shortages grow, hospitals turn to artificial intelligence (AI) and scheduling tools to optimize resources, ...